The global ocular pain treatment
market is expected to witness considerable growth
due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing
number of lifestyle related ocular diseases. In addition, increasing geriatric
population and increasing disposable income are further supporting the growth
of the global ocular pain market.
Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market
The
pharmaceutical companies are actively involved in the research and development
of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform
technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc.,
is nanotechnology based products for the treatment of ocular pain.
A
large number of pharmaceutical companies are constantly working for the
research and development of ocular pain treatment. However, certain factors
such as high treatment cost, less awareness about the eye disease among
population and lack of favorable government policy are the key factors hindering the growth of the global
market during the forecast period.
Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc., Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.
No comments:
Post a Comment